Stocks Health care BTAI
NASDAQ · Health careBioXcel Therapeutics, Inc. (BTAI)
BioXcel Therapeutics, Inc. brought in $742K of revenue over the twelve months to June 30, 2026, down 14.5% from a year earlier. It posted a net loss of $70.9M. In fiscal 2025 capital spending exceeded operating cash flow by $57.6M. At June 30, 2026 it held $12.8M in cash against $104.5M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
What BioXcel Therapeutics, Inc. does
BioXcel Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BTAI.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $642K | -$69.9M | -$5.73 | -$57.6M |
| 2024 | $2.3M | -$59.6M | -$23.51 | -$72M |
| 2023 | $1.4M | -$179.1M | -$98.33 | -$155M |
| 2022 | $375K | -$165.8M | -$94.65 | -$135.5M |
| 2021 | n/a | -$106.9M | -$64.75 | -$82.6M |
| 2020 | n/a | -$82.2M | -$60.60 | -$66.7M |
Full financial statements: income, balance sheet and cash flow
Where BTAI ranks in Health care
Latest SEC filings
What BioXcel Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 1, 2026New debt 8-K
- August 28, 2026
- August 25, 2026
- August 24, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 52% to $182K versus the same quarter last year; diluted EPS -$0.49 versus -$2.45.
- August 11, 2026
- August 3, 2026
- July 6, 2026
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running BioXcel Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 15, 2026 | Mehta VimalCEO and President, Director | Exercised options | 219 | - |
| June 15, 2026 | Yocca FrankChief Scientific Officer | Exercised options | 35 | - |
| June 15, 2026 | Steinhart Richard IChief Financial Officer | Exercised options | 35 | - |
| June 15, 2026 | Rodriguez JavierSee Remarks | Exercised options | 35 | - |
| May 20, 2026 | Mehta VimalCEO and President, Director | Soldpre-planned (10b5-1) | 19,419 | $21.1K |
| May 20, 2026 | Steinhart Richard IChief Financial Officer | Soldpre-planned (10b5-1) | 6,845 | $7.4K |
| May 20, 2026 | Rodriguez JavierSee Remarks | Soldpre-planned (10b5-1) | 6,560 | $7.1K |
| May 20, 2026 | Yocca FrankChief Scientific Officer | Soldpre-planned (10b5-1) | 6,845 | $7.4K |
| May 4, 2026 | Mehta VimalCEO and President, Director | Exercised options | 49,758 | - |
| May 4, 2026 | Steinhart Richard IChief Financial Officer | Exercised options | 17,500 | - |
| May 4, 2026 | Rodriguez JavierSee Remarks | Exercised options | 17,500 | - |
| May 4, 2026 | Yocca FrankChief Scientific Officer | Exercised options | 17,500 | - |
Who owns BTAI
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vimal Mehta13D, may seek influence with 2 related filers | 23.5% | June 6, 2024 |
| Millennium Management LLC13G, passive with 3 related filers | 8.4% | February 9, 2026 |
Largest institutional holders
Insiders
4 insiders reported holding 149,200 shares in total, about $11K at the last price.
| Holder | Shares |
|---|---|
| Mehta VimalCEO and President, Director | 69,817 |
| Rodriguez JavierSee Remarks | 26,838 |
| Steinhart Richard IChief Financial Officer | 26,335 |
| Yocca FrankChief Scientific Officer | 26,210 |
Questions about BTAI
What does BioXcel Therapeutics, Inc. do?
BioXcel Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BTAI.
Is BioXcel Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $70.9M on revenue of $742K.
How much revenue does BioXcel Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 BioXcel Therapeutics, Inc. reported revenue of $742K. That is 14.5% less than a year earlier.
When did BioXcel Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the new debt from September 1, 2026.
Similar companies
Compare BTAI with
Follow BTAI
Get an email when BioXcel Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow BTAI: get an email when it filesWhere the numbers come from
Financial figures are the values BioXcel Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.